Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy
Purpose of Review
Cellular therapy using T cells modified to express chimeric antigen receptors (CAR-T cells) has had striking success in patients that have failed previous treatment for CD19+ B cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), or acute lymphoblastic leukemia (ALL). Curative therapy for this group of diseases has previously been limited to allogeneic hematopoietic cell transplantation HCT (alloHCT). The recent results of CAR-T cell therapy raise the question of how best to integrate CAR-T cell therapy and alloHCT in the care of these patients.
Within the past 2 years, results from larger trials and increased follow-up of patients treated with CD19 CAR-T cell therapy suggest that some may achieve durable remission without transplant.
The balance of efficacy and toxicity for CAR-T cell therapy and alloHCT vary by disease type, disease status at the time of treatment, patient characteristics, and the specific therapy employed. There are early signals that subsequent transplantation of patients who have achieved remission with CAR-T may be a potentially viable (though expensive) strategy.
KeywordsCord blood Stem cell transplant CAR-T cells CD-19 CD-20 BCMA
This work was supported by a T32 institutional training grant from the National Institutes of Health to Jacob Appelbaum (5T32HL007093).
Compliance with Ethical Standards
Conflict of Interest
Jacob S. Appelbaum and Filippo Milano declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18 Case reports describing the first two patients to receive meaningful doses of CAR-T cells for hematologic malignancy.PubMedPubMedCentralCrossRefGoogle Scholar
- 2.Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099–102.PubMedPubMedCentralCrossRefGoogle Scholar
- 3.• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44 Phase 2 trial treating 111 patients with 2 × 10 6 CAR-T (ZUMA-1). PubMedPubMedCentralCrossRefGoogle Scholar
- 4.• Schuster SJ, Bishop M, Tam C, Waller EK, Borchmann P. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. In: ASH Abstract [Internet]. 2017 [cited 2018 Mar 21]. p. 577. Available from: https://ash.confex.com/ash/2017/webprogram/Paper105399.html. Initial report of the phase 2 trial treating 99 patients with tisengenlecleucel for r/r DLBCL.
- 5.•• Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492–500 Study provides rationale and data to support the cooperativity of CD4 and CD8 cells in therapeutic efficacy. PubMedCrossRefGoogle Scholar
- 6.•• Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells. Sci Transl Med. 2016;8(355):355ra116–6 Careful analysis of patients treated with CAR-T identified pitfalls of CAR-T cell therapy, including the development of immune responses to CAR proteins, predictors of cytokine release syndrome, dynamics of CAR-T expansion, and the importance of fludarabine in lymphodepletion. Google Scholar
- 8.•• Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59 Long-term follow-up provides insight into the outcomes of patients who achieve remission by CAR-T cell therapy and the importance of differences in T cell persistence between various CAR-T cell products.PubMedCrossRefGoogle Scholar
- 10.Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, Lima M de, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(4):319–326.Google Scholar
- 13.Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671–7.PubMedCrossRefGoogle Scholar
- 17.• Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–71 First study to demonstrate safety of CAR-T cells in humans.PubMedPubMedCentralCrossRefGoogle Scholar
- 18.Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.Google Scholar
- 20.Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–21.PubMedPubMedCentralCrossRefGoogle Scholar
- 23.•• Crump M, Neelapu SS, Farooq U, Neste EVD, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8 Retrospective analysis illustrating the poor prognosis of patients with r/r DLBCL and justifying the use of CAR-T cell therapy. PubMedPubMedCentralCrossRefGoogle Scholar
- 24.• Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54 Results of 28 patients treated with r/r DLBCL or follicular lymphoma showing high response rates. PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Nagle SJ, Kaitlin W, Schuster Stephen J, Nasta Sunita D, Edward S, Rosemarie M, et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol. 2013;88(10):890–4.PubMedCrossRefGoogle Scholar
- 26.• Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood. 2017;130(Suppl 1):581–1 Phase 2 study of 74 patients treated with JCAR017 for aggressive lymphoma. Double- and triple-hit patients had an ORR of 81%. Defined composition of the CAR product revealed a therapeutic window of improved safety. Google Scholar
- 27.•• Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, et al. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transplant. 2015;21(12):2091–9 In considering transplant of low-grade lymphomas, this paper illustrates the differences in short- and long-term outcomes with auto- versus alloHCT. In addition, it provides a comparison point for the success of treatments, i.e., 5-year OS of 66 to 74%. PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245–56.PubMedPubMedCentralCrossRefGoogle Scholar
- 34.•• Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–10 Study showing target antigen loss is a key method of therapeutic escape.PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–7.Google Scholar
- 37.Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(11):1863–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. ASH Educ Program Book. 2014;2014(1):244–9.Google Scholar
- 43.• Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 116(24):5568–5574. References 32 and 33 provide benchmarks for outcomes of experimental therapies for relapsed/refractory ALL. Google Scholar
- 47.Kato K, Miyamoto T, Yonemoto K, Uchida N, Ogawa H, Fukuda T, et al. Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapse of hematological malignancies after first allo-HSCT. Blood. 2014;124(21):3947–7.Google Scholar
- 48.Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, et al. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2017;123(14):2671–9.PubMedCrossRefGoogle Scholar
- 50.Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254–4.Google Scholar
- 51.Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. A multicenter open-label, phase 1b/2 study of ibrutinib in combination with lenalidomide and rituximab in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2016;128(22):473–3.Google Scholar
- 53.van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant J-P, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342–8.PubMedCrossRefGoogle Scholar
- 56.Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108(8):2540–4.PubMedCrossRefGoogle Scholar
- 60.Zinzani PL, Topp MS, Yuen SL, Rusconi C, Fleury I, Pro B, et al. Phase 2 study of venetoclax plus rituximab or randomized VEN plus bendamustine+rituximab (BR) versus BR in patients with relapsed/refractory follicular lymphoma: interim Data. Blood. 2016;128(22):617–7.Google Scholar
- 61.Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2017;1:blood-2017-09-804641.Google Scholar
- 66.• Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood. 2016;128(22):1147–7 Initial safety study of BCMA CAR-T cells.Google Scholar
- 67.Berdeja JG, Lin Y, Raje N, Munshi N, Siegel D, Liedtke M, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood. 2017;130(Suppl 1):740–0.Google Scholar
- 68.• Updated results of ongoing multicenter phase I study of bb2121 anti-BCMA CAR T cell therapy continue to demonstrate deep and durable responses in patients with late-stage relapsed/refractory multiple myeloma at ASCO Annual Meeting (NASDAQ:CELG) [Internet]. [cited 2018 Jul 18]. Available from: http://ir.celgene.com/releasedetail.cfm?releaseid=1069096. Impressive safety and efficacy data with preserved safety profile for myeloma.
- 69.• Chekmasova AA, Horton HM, Garrett TE, Evans JW, Griecci J, Hamel A, et al. A novel and highly potent CAR T cell drug product for treatment of BCMA-expressing hematological malignances. Blood. 2015;126(23):3094–3094. Evidence that BCMA CAR-T cells can recognize target cells with < 1000 copies of target antigen on their surface. Google Scholar
- 70.•• Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32(4):506–519.e5 Key paper illustrating the challenges of identifying suitable antigens for CAR-T cells to treat myeloid malignancies. PubMedCrossRefGoogle Scholar
- 72.Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;25:1.Google Scholar
- 74.Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139–9.Google Scholar
- 75.Bishop DC, Xu N, Tse B, O’Brien TA, Gottlieb DJ, Dolnikov A, et al. PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts. Mol Ther [Internet]. 2018 10 [cited 2018 Jul 27];0(0). Available from: https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(18)30210-7.
- 81.Segal Eric, Martens Michael, Wang Hai-Lin, Brazauskas Ruta, Weisdorf Daniel, Sandmaier Brenda M., et al. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-cell acute lymphoblastic leukemia. Cancer. 2017;123(17):3346–3355.Google Scholar
- 83.Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood. 2017;1:blood-2017-06-793141.Google Scholar
- 84.Turtle CJ, Hay KA, Juliane G, Hanafi L-A, Li D, Chaney C, et al. Biomarkers of cytokine release syndrome and neurotoxicity after CD19 CAR-T cells and mitigation of toxicity by cell dose. Blood. 2016;128(22):1852–2.Google Scholar
- 86.Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2(12):1583–9.PubMedPubMedCentralCrossRefGoogle Scholar